Latest News about Psychedelic/Assisted Therapies
Recent news which mentions Psychedelic/Assisted Therapies
Alternative Treatment For Bipolar II Depression: Psilocybin Safe And Effective, AMA Study Finds
December 06, 2023
Tickers
CMPS
From Benzinga
NFL's Jon Feliciano Takes His Psychedelics Advocacy To The Field: Chooses MAPS As His "My Cleats, My Cause"
December 05, 2023
From Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
From Benzinga
Braxia Scientific's Q2 2024: Cash Burn Over But Income Low, What's Next For Psychedelics Company?
December 04, 2023
From Benzinga
Super Model Chrissy Teigen Talks About Ketamine Therapy Session, Says She Saw 'Space & Time'
December 04, 2023
From Benzinga
Cybin's Novel Psilocybin Topline Data: 79% Remission In Major Depression Symptoms, What's Next?
December 03, 2023
Tickers
CYBN
From Benzinga
Red Light Holland, With $12M Cash Balance & Revenue Up 33%, Remains 'Confident' In Business Strategy
November 29, 2023
Tickers
TRUFF
From Benzinga
Seelos Therapeutics' $5.55M Public Offering As Stock Drop 35%
November 29, 2023
From Benzinga
Defense Dept. Funds Ketamine Study For PTSD Treatment In 600 Service Members & Veterans
November 27, 2023
From Benzinga
From Benzinga
Global Psychedelics: Australia's Prescription Guidelines, New Zealand's Meth Addiction Treatment
November 24, 2023
From Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
From Benzinga
Clearmind Medicine's Reverse Stock Split And Nasdaq Delisting Notice
November 21, 2023
Tickers
CMND
From Benzinga
Three Johns Hopkins Psychedelics Professors Call The Shots On Live Q&A: Knowns, Unknowns, Regulations & Hopes
November 20, 2023
From Benzinga
From Benzinga
GH Research: Steady Expenses And $229M Cash Position For 2026 Runway
November 14, 2023
Tickers
GHRS
From Benzinga
Atai Life Sciences' Q3 Earnings: Near $20M Burned QoQ, Says Funding 'Sufficient' To Streamline 2026
November 14, 2023
From Benzinga
Psyched: Veterans & Psychedelics, $100M IPO, Cybin's $64M Offering, Worldwide Events & More
November 12, 2023
From Benzinga
Veterans Day: Can Psychedelic Treatment Help Stem PTSD-Related Suicides Among Veterans?
November 11, 2023
From Benzinga
Cybin Launches Five-Day Units Offering For Up To $64M, Suspends Prior LPC Funding Deal
November 10, 2023
Tickers
CYBN
From Benzinga
Worldwide Psychedelics Events: Miami, Croatia, D.C., France, UK, NY, Oregon, Arizona & SXSW
November 09, 2023
From Benzinga
Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
November 08, 2023
Tickers
PMBHF
From Benzinga
Psychedelics Reform In California, Wisconsin, Illinois, Massachusetts & Pennsylvania
November 05, 2023
From Benzinga
MindMed Q3 2023: Financials, Business Funded By 2026 If LSD Pipeline Milestones Achieved
November 03, 2023
Tickers
MNMD
From Benzinga
Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find
November 01, 2023
Tickers
CYBN
From Benzinga
From Benzinga
EXCLUSIVE: Becoming Compliant In Today's Legal Psychedelics Markets With Allay Consulting
October 26, 2023
From Benzinga
Cybin Officially Owns Small Pharma: Plans For New 'International Leader' In Psychedelic Therapeutics
October 23, 2023
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
